Maintenance Capecitabine and Bevacizumab Versus Bevacizumab Alone After Initial First-Line Bevacizumab and Docetaxel for Patients with Her2-Negative Metastatic Breast Cancer (Imelda): a Randomised, Open-Label, Phase 3 Trial